Warnex Inc.

Warnex Inc.

February 13, 2006 10:49 ET

Warnex's supplier resumes manufacturing and sale of PCR thermal cyclers

LAVAL, QC, Feb. 13 - Warnex Inc. (TSX:WNX) announced today that it
has been advised that Bio-Rad Laboratories and MJ Research have reached a
settlement agreement with Applied Biosystems, an Applera Corporation business,
which allows them to resume the manufacturing, selling and servicing of PCR
thermal cyclers in the United States. Currently, the Warnex™ Rapid Pathogen
Detection System incorporates MJ Research PCR thermal cyclers in its platform
for performing proprietary pathogen detection tests.

More details concerning this settlement agreement are disclosed in the
press release issued today by Applied Biosystems, which may be consulted at
www.appliedbiosystems.com.

About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods to
GMO testing. Our development pipeline includes applications in the detection
of viruses, toxins, yeasts, and fungi, as well as meat speciation and
bioterrorism. Warnex's profitable and growing analytical, bioanalytical, and
clinical service groups offer a variety of quality control services, method
development and validation, contract R&D, bioavailability and bioequivalence
studies for clinical trials, and medical laboratory testing.

Warnex is a trademark of Warnex Inc.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing, R&D
of new Warnex products, manufacturing and laboratory facilities, suppliers,
key employees, key customers, financial resources and credit risk, government
regulations, foreign currency risk and volatility of share price, and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to the
heading Risks and Uncertainties in the Management's Discussion and Analysis
for the third quarter ended on September 30, 2005, which can be found at
www.sedar.com. Consequently, actual results may differ materially from the
anticipated results expressed in these forward-looking statements.

Contact Information